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Abstract
Introduction: Glycosylated hemoglobin (HbA1c) concentrations measured in clinical chemistry laboratories show large differences between their 
interlaboratory reported values. Laboratory measurements of quality performance should be based on quantitative data. The sigma metrics model 
provides an objective method for the assessment of current HbA1c assays and is useful in quality management planning. The aim of our study was 
to evaluate the analytical performance of the MQ-2000 PT HbA1c analyzer test results in the context of our operating conditions on the sigma scale.
Materials and methods: The coefficient of variation was determined from the calculated mean and standard deviation evaluated from inter-
nal quality control (QC) (N = 168 days) (Shanghai Huachen Biological Reagent Co. Ltd, China) data, and records of external quality data (KBUDEK, 
İstanbul, Turkey) measured in the period from May to November 2013 were used to determine the bias. The resulting data and total allowable error 
rate (TEA = 10%) from the Clinical Laboratory Improvement Amendments of 1988 (CLIA’88) were used to calculate the sigma level. 
Results: The calculated coefficient of variations (CVs) at the two levels, normal (QC1 = 36.6 ± 2.38 mmol/mol) and pathological (QC2 = 84.7 ± 2.68 
mmol/mol), were 6.5% and 3.1%, respectively. The average bias between the external QC and MQ-2000 PT during the study period was 4.3%. The 
calculated average sigma value was 1.19.
Conclusions: The MQ-2000 PT HbA1c is a new analyser in the market; there is need for improvement and the method should be controlled with 
greater attention to ensure quality. 
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HbA1c testing is important for the long-term con-
trol of glycaemia in diabetic patients. The diagnos-
tic cut-off for HbA1c has been set at 48 mmol/mol, 
with patients being managed to maintain their 
HbA1c at ≤ 53 mmol/mol (1,2). However, the meth-
ods currently used to measure HbA1c concentra-
tions in clinical chemistry laboratories show large 
differences between their interlaboratory report-
ed values, making comparisons of results from dif-
ferent laboratories difficult (3).
High analytical quality of the HbA1c test can be 
achieved by using commercial dedicated high per-
formance liquid chromatography (HPLC) systems 
and monitoring their performance by means of 
QC programs with appropriate materials that will 
increase the operator’s confidence in their perfor-
mance. Although current QCs in laboratory medi-
cine tend to focus on the performance and effi-
ciency of analytical processes, they still have room 
for improvement (4-6).
Errors in analytical measurements fall into two 
main categories: random and systematic errors. 
The typical analytical performance characteristics 
of inaccuracy and imprecision are basic parame-
ters of method performance validation for system-
atic and random errors. These parameters are rep-
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resented by the coefficient of variation (CV) and 
bias, and they can be used to calculate the total er-
ror (TE) (1). The total analytical error (TEA) is a use-
ful measurement for assessing laboratory assay 
quality that combines the effects of systematic 
and random errors, which makes the validation re-
sults of complete analytical processes more evi-
dent (7). 
Six sigma metrics combine bias, precision, and 
TEA, and can be used for assessing the quality of 
the analytic phase (8). The exact number of errors 
made can be quantified by employing sigma met-
rics in the laboratory. A high sigma value indicates 
that a laboratory’s reports of false test results are 
low. With the aid of Six Sigma principles and met-
rics, it is possible to ensure that the desired quality 
is achieved. Recently, the International Federation 
of Clinical Chemistry and Laboratory Medicine 
(IFCC) Task Force on the Implementation of HbA1c 
Standardization (TF-HbA1c) suggested a consen-
sus statement regarding the quality targets for 
HbA1c with respect to the sigma metrics model as 
the model of choice (5).
In Turkey, public procurement laws include regula-
tions concerning emphasis on the lowest bid ac-
cording to unit prices. Therefore, decisions about 
which HbA1c analyzer to buy depends on price in 
our health system. The MQ-2000 PT HbA1c analyz-
er uses HPLC with ion exchange chromatography, 
and has been used for HbA1c quantification in our 
laboratory. Although there are no legally enforce-
able responsibilities, there is a need to evaluate 
the performance of the MQ-2000 PT HbA1c analyz-
er test results. 
The aim of our study was to evaluate the analytical 
performance of the MQ-2000 PT HbA1c analyzer 
test results in the context of our operating condi-
tions on the sigma scale.
Materials and methods
Study design 
The present study was conducted in the clinical 
laboratory of the Şevket Yılmaz Research and Edu-
cation Hospital. The study was approved by our in-
stitutional ethics committee and was in compli-
ance with the Helsinki Declaration. The six-month 
(May to October 2013; N = 168 days) internal and 
external QCs (which were in May, July, September, 
and November) of HbA1c test results were extract-
ed for this study. 
Methods
The MQ-2000 PT HbA1c analyzer (Shanghai Hui 
Zhong Medical Technology Co., Ltd., China) uses 
high-performance liquid chromatography (HPLC) 
and separates HbA1c by cation exchange. The sta-
tionary phase is a weakly acidic cation exchange 
column, with a group that can exchange cations 
and can combine with non-glycated hemoglobin 
with a positive charge by electrostatic interactions. 
The glycated hemoglobin cannot combine with 
the stationary phase because it has no charge. The 
separated hemoglobin fractions are monitored by 
means of absorption of light, and the chromato-
gram obtained is recorded and stored by the inter-
nal computer. A software program in the instru-
ment performs the analysis of the chromatogram. 
The HbA1c concentration is calculated as the per-
centage of the HbA1c peak area relative to the to-
tal hemoglobin peak area in the chromatogram. 
According to the manufacturer, the analyzer could 
detect HbA1c concentrations between 20 mmol/
mol and 162 mmol/mol.
All reagents, calibrators, and controls used were 
provided by the manufacturer. Calibrations were 
performed as recommended by the manufacturer 
(Lot PT HbA1c12334C; Shanghai Huachen Biologi-
cal Reagent Co. Ltd, China) (40.0 mmol/mol and 90 
mmol/mol). 
Two levels of internal QC materials, diabetes con-
trol Levels 1 (mean = 35.5 mmol/mol, range: 30.1–
43.2 mmol/mol) and 2 (mean = 84.7 mmol/mol, 
range: 71.9–97.5 mmol/mol) (Lot 33850; Huachen 
Biological Reagent Co. Ltd, China), were assayed in 
duplicate twice daily during the study period. The 
manufacturer’s package inserts were followed, 
and open vial controls were stored at 2–8 °C for a 
maximum of seven days as per the manufacturer’s 
directions. The same lot numbers were used dur-
ing the study period.
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Internal statistical QC data for the study period 
were extracted from the records of the MQ-2000PT 
HbA1c analyzer. The CV (%) was calculated by us-
ing the mean from six months (N = 168) of internal 
QC. 
Bias is derived from the external QC reports, which 
we participated in in the KBUD (Klinik Biyokimya 
Uzmanları Dernegi, Istanbul, Turkey) external QC 
program for HbA1c. Our results were compared to 
those of 32–38 laboratories using the HPLC with 
ion exchange chromatography method once eve-
ry two calendar months. 
The TEA is the amount a test result may deviate 
from the “true value” and still be acceptable. A TEA 
value of 10% for Hba1c was taken from Clinical 
Laboratories Improvement Act (CLIA) regulations, 
and sigma levels and critical systematic error were 
calculated. The size of the medically important 
systematic error is called the critical systematic er-
ror (9).
Statistical analysis
Data were evaluated using SPSS version 21.0 (SPSS 
Inc., Chicago, IL, USA). Means, standard deviations, 
and CVs were calculated. CV (%) was calculated 
from the internal QC data over the six-month peri-
od using the following equation:
CV (%) = (standard deviation × 
100) / laboratory mean(IQC)
Bias was calculated from the external quality as-
sessment records using the following formula:
Bias (%) = (mean of all laboratories using 
the same instrument and method - our 
mean) / (mean of all laboratories using the 
same instrument and method) × 100
Sigma levels were calculated using the formula as 
follows:
Process sigma = (% TEA - % “biasEQC”) / % CVIQC (5).
Assessment of the quality on the sigma scale of six 
provides an objective assessment of the analytical 
performance. The critical systematic errors were 
calculated by the following equation (9):
SEcrit = [(TEa - bias)/sD] – 1.65
where the factor 1.65 was chosen to minimize the 
risk of erroneous test results at 5%.
Results
Two sets of quality control samples, normal (QC1) 
and pathological (QC2), were analyzed. Their labo-
ratory means were 36.6 ± 2.38 mmol/mol and 84.7 
± 2.68 mmol/mol, respectively. Their calculated 
CVs were 6.5% and 3.1%, respectively. 
We studied four external quality controls during 
the study period. In May and November, our Hba1c 
test results were 34.4 mmol/mol and 31.1 mean, 
while the corresponding biases were 0.8% and 
5.5%, respectively. In July and September, Hba1c 
test results were 92.4 mmol/mol and 84.7 mmol/
mol, while the corresponding biases were 9.7% 
and 1.1%. The average bias between the external 
quality control and the MQ-2000 PT during the 
study period was 4.2% (Table 1). 
Period N* Lab’s Result Mean of group* Bias (%) MU
May 32 34.4 34.0 0.8 0.04
July 38 92.4 82.1 9.7 0.11
September 35 84.7 83.5 1.1 0.11
November 33 31.1 34.3 –5.5 0.08
N - Number of participants using the same method; MU - Measurement uncertainty
*Mean of the results of the laboratories using the HPLC method
Table 1. External quality control data.
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The calculated average sigma metric was 1.19, and 
the critical systematic error was –0.46 (7). The 
traceability report from KBUD showed that the un-
certainty of EQA samples was 0.06 for low control 
levels and 0.11 for high control levels, respectively. 
Three of the SDI values were 1.25 or less, which is 
considered acceptable. 
Discussion
The IFCC Task Force on Implementation of HbA1c 
Standardization suggests initially setting a sigma 
of 2 for routine laboratories, which is the starting 
point for improved quality, and is suitable for esti-
mating the quality status of HbA1c of a single labo-
ratory and a single manufacturer. We obtained a 
sigma < 1.5 for both QC levels, showing that the 
analytical quality of the MQ-2000 PT HbA1c ana-
lyzer was not appropriate when evaluated on the 
sigma scale. A sigma of 2 is defined as the mini-
mum allowable value for routine performance, 
based on the need to evaluate the ability of the 
device to effectively distinguish an HbA1c of 46 
mmol/mol from an HbA1c of 47 mmol/mol, since 
two different treatment options exist at these two 
values. This means that patients are at risk of re-
ceiving a wrong clinical decision, especially if their 
HbA1c results were close to the clinical decision 
limit. Similar to our findings, it has been shown 
that a number of laboratories in Europe do not 
meet the 2-sigma criteria for HbA1c test results (5).
Analytical reproducibility in Hba1c measurement 
is important for monitoring diabetic patients. 
Changes in results between two HbA1c test results 
should reflect responses to treatment, and an opti-
mal imprecision goal for HbA1c of 2.1% has been 
proposed (10,11). This criterion is very strict, how-
ever, and difficult to meet, with an imprecision of 
3% CV being a more realistic target (12). Neither of 
the calculated CVs at the two levels, for normal 
(QC1) and pathological (QC2) internal QCs, met 
these desired levels. If we used a precision value 
calculated for a shorter period of time, it could re-
sult in lower estimates of imprecision and higher 
sigma metrics, but we calculated a long-time ana-
lytical precision, which might explain our high CV. 
In our method with CV%s of 4%, results would 
need to differ by more than 0.8% to be confident 
that there has been a clinically significant change 
in glycemic status. Users should be informed not 
to change therapy on the basis of a small differ-
ence between two consecutive Hba1c values. 
Both analytical bias and imprecision (CV) influence 
the probability of a laboratory passing a sigma of 2 
criterion. To reliably detect clinically significant an-
alytic errors, clinical laboratories should use HbA1c 
methods that have a bias that approaches zero in 
external quality control programs (5). As we focus 
on lower Hba1c levels that signal disease, we 
should be more alarmed that smaller fluctuations 
will change diagnoses. Our biases were very high, 
which is why we did not use recalibration to im-
prove accuracy during EQAS tests. Also, the uncer-
tainty in the calibration of our routine Hba1c pro-
cedure is traceable only to a manufacturer’s inter-
nal working calibrator.
One major limitation of this study was that the ex-
ternal quality control program in which we partici-
pated was based on a peer group rather than an 
accuracy program. Another limitation of this study 
is that we used calibrator and control material pro-
vided by the tested analyzer. Comparability can be 
assured only by the principle of traceability to 
higher-order standards, but the metrological 
traceability of the controls and calibrators were 
uncertain as to which responsibility of correction 
is primarily the manufacturer’s.
Conclusions
Standardization and monitoring of the analytical 
performance of HbA1c tests is critical, and there is 
a need for nationwide use of internationally stand-
ardized assays and a certification program for lab-
oratories. Laboratories involved in the long-term 
testing of HbA1c must improve the quality of their 
analytical testing to ensure clinically valid results. 
The MQ-2000 PT HbA1c is a new analyzer in the 
market; there is need for improvement, and the 
method should be controlled with greater atten-
tion to ensure quality. 
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